S&P 500   3,855.46
DOW   31,175.68
QQQ   324.42
S&P 500   3,855.46
DOW   31,175.68
QQQ   324.42
S&P 500   3,855.46
DOW   31,175.68
QQQ   324.42
S&P 500   3,855.46
DOW   31,175.68
QQQ   324.42
Log in

Medpace Stock Forecast, Price & News

+2.84 (+2.01 %)
(As of 01/20/2021 02:43 PM ET)
Today's Range
Now: $143.99
50-Day Range
MA: $139.48
52-Week Range
Now: $143.99
Volume5,307 shs
Average Volume216,375 shs
Market Capitalization$5.15 billion
P/E Ratio44.03
Dividend YieldN/A
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Medpace logo


Overall MarketRank

1.19 out of 5 stars

Medical Sector

826th out of 1,928 stocks

Commercial Physical Research Industry

15th out of 42 stocks

Analyst Opinion: 1.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:MEDP



Sales & Book Value

Annual Sales$860.97 million
Cash Flow$3.89 per share
Book Value$20.16 per share


Net Income$100.44 million


Market Cap$5.15 billion
Next Earnings Date2/15/2021 (Confirmed)
+2.84 (+2.01 %)
(As of 01/20/2021 02:43 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Medpace (NASDAQ:MEDP) Frequently Asked Questions

How has Medpace's stock been impacted by Coronavirus (COVID-19)?

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MEDP shares have increased by 71.4% and is now trading at $143.36.
View which stocks have been most impacted by COVID-19

Is Medpace a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Medpace?

Wall Street analysts have given Medpace a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Medpace wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, February 15th 2021.
View our earnings forecast for Medpace

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Monday, February 15th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) released its quarterly earnings data on Saturday, October, 31st. The company reported $1.09 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.07 by $0.02. The firm had revenue of $230.37 million for the quarter, compared to analyst estimates of $223.56 million. Medpace had a return on equity of 17.67% and a net margin of 13.87%. Medpace's revenue for the quarter was up 6.5% compared to the same quarter last year. During the same period last year, the company posted $0.71 EPS.
View Medpace's earnings history

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY20 earnings guidance on Monday, October, 26th. The company provided EPS guidance of $3.62-3.83 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.95. The company issued revenue guidance of $880-920 million, compared to the consensus revenue estimate of $903.50 million.

What price target have analysts set for MEDP?

6 Wall Street analysts have issued 12 month target prices for Medpace's stock. Their forecasts range from $75.00 to $135.00. On average, they expect Medpace's stock price to reach $103.00 in the next year. This suggests that the stock has a possible downside of 28.2%.
View analysts' price targets for Medpace
or view Wall Street analyst' top-rated stocks.

Are investors shorting Medpace?

Medpace saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 996,700 shares, an increase of 32.1% from the December 15th total of 754,400 shares. Based on an average daily volume of 248,700 shares, the days-to-cover ratio is currently 4.0 days. Approximately 3.6% of the shares of the stock are short sold.
View Medpace's Short Interest

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

Who are Medpace's key executives?

Medpace's management team includes the following people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 64, Pay $592.56k)
  • Mr. Jesse J. Geiger, CFO & COO of Laboratory Operations (Age 46, Pay $418.98k)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 57, Pay $633.22k)
  • Mr. Stephen P. Ewald, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 51, Pay $415.79k)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing
  • Mr. Weimin Gai MS, Sr. VP of Biometrics
  • Mr. Daniel O'Leary, Sr. VP of Medical Department
  • John T. Wynne, Sr. VP of Commercial Operations & Clinical Pharmacology Unit
  • Mr. Kevin M. Brady, Exec. Director of Fin.

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of retail and institutional investors. Top institutional investors include Boston Trust Walden Corp (1.42%), Tributary Capital Management LLC (0.49%), Scout Investments Inc. (0.29%), McGuire Investment Group LLC (0.14%), Exchange Traded Concepts LLC (0.03%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace

Which major investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Tributary Capital Management LLC, and State of Alaska Department of Revenue. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace
or view top insider-selling stocks.

Which major investors are buying Medpace stock?

MEDP stock was bought by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Exchange Traded Concepts LLC, Mountain Capital Investment Advisors Inc, McGuire Investment Group LLC, Scout Investments Inc., Crossmark Global Holdings Inc., Louisiana State Employees Retirement System, and Sheets Smith Wealth Management.
View insider buying and selling activity for Medpace
or or view top insider-buying stocks.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $143.36.

How big of a company is Medpace?

Medpace has a market capitalization of $5.13 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.